Vor Biopharma strengthens board following $150M private placement

Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potentialVor Biopharma ( (VOR) ) has provided an update. On December 15, 2025, Vor Bio entered into a securities purchase agreement for a $150 million private placement of 13,876,032 common shares at $10.81 each to a group of institutional and accredited healthcare specialist investors, including RA Capital Management and Forbion, without using a placement agent. The company plans to use the proceeds to fund the clinical development of its lead asset telitacicept, including an ongoing global Phase 3 trial in myasthenia gravis and a planned global Phase 3 trial in primary Sjögren’s disease, and for general corporate purposes, while concurrently granting investors registration rights for resale of the shares and allowing Forbion to appoint one director to Vor Bio’s board. On December 17, 2025, board member Sarah Reed resigned without a dispute, and on December 18, 2025, Vor Bio appointed RA Capital’s Andrew Levin as an independent Class II director and Forbion’s Wouter Joustra as an independent Class III director, moves that deepen the company’s ties with major life sciences investors and bring additional venture and capital markets expertise to its board as it advances late-stage autoimmune programs. The most recent analyst rating on (VOR) stock is a Buy with a $43.00 price target. To see the full list of analyst forecasts on Vor Biopharma stock, see the VOR Stock Forecast page. Spark’s Take on VOR Stock According to Spark, TipRanks’ AI Analyst, VOR is a Underperform. Vor Biopharma faces significant financial challenges, with no revenue and ongoing losses. Technical indicators suggest weak market sentiment, and the lack of positive valuation metrics further underscores the risk. Investors should be cautious due to the high financial risk and uncertainty. To see Spark’s full report on VOR stock, click here. More about Vor Biopharma Vor Bio, listed on Nasdaq as VOR, is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases. The company is centered on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. Average Trading Volume: 1,557,684 Technical Sentiment Signal: Sell Current Market Cap: $346.6M